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Drug synergy allows a therapeutic effect to be achieved with lower doses of component drugs. Drug
synergy can result when drugs target the products of genes that act in parallel pathways (‘speciﬁc
synergy’). Such cases of drug synergy should tend to correspond to synergistic genetic interaction
between the corresponding target genes. Alternatively,‘promiscuous synergy’ can arise when one
drug non-speciﬁcally increases the effects of many other drugs, for example, by increased
bioavailability.Toassess therelativeabundance ofthesedrugsynergytypes, weexamined 200pairs
ofantifungaldrugsinS.cerevisiae.Wefound38antifungalsynergies,37ofwhichwerenovel.While
14 cases of drug synergy corresponded to genetic interaction, 92% of the synergies we discovered
involvedonlysixfrequentlysynergisticdrugs.Although promiscuityof fourdrugs can beexplained
under the bioavailability model, the promiscuity of Tacrolimus and Pentamidine was completely
unexpected. While many drug synergies correspond to genetic interactions, the majority of drug
synergies appear to result from non-speciﬁc promiscuous synergy.
Molecular Systems Biology 7: 544; published online 8 November 2011; doi:10.1038/msb.2011.71
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Introduction
Pathogens or tumors that do not respond to single treatments
maybeamenabletocombineddrugtreatments(Yehetal,2006;
Azmi et al, 2010). Synergistic drug pairs have special potential
for treatment, since they allow a desired effect to be achieved
with a lower total dose of administered medicine (Greco et al,
1995). Theoretical and experimental studies have shown that
drugs that exhibit synergy for a speciﬁc effect are usually not
synergisticforsideeffects(Leharetal,2009;Owensetal,2010).
These considerations make synergistic drug pairs ideal
candidates for treatment of pathogens or tumors.
As a result of their medicinal potential, synergistic drug pairs
are sought both experimentally and theoretically. Large-scale
experimental drug synergy screens have found that synergistic
drugpairsarerare(4–10%)(Borisyetal,2003;Zhangetal,2007;
Farha and Brown, 2010). Therefore, methods which predict
synergistic drug combinations have been developed, such as
networkanalysisofexpressionproﬁles(Nelanderetal,2008),or
clustering of chemogenomic proﬁles of drug perturbations
(Jansen et al, 2009). In addition, perturbations with multiple
drugs have been used to understand the organization and
robustness of biological systems (Lehar et al, 2007).
One model for drug synergy is the parallel pathway
inhibition model, which suggests that two drugs will be
synergistic if they inhibit two proteins on parallel pathways
essential for an observed phenotype (Yeh et al, 2009). To ﬁnd
protein pairs in parallel pathways, we used synergistic genetic
interactions, where two combined genetic perturbations result
in a phenotype that is more severe than expected (Tong et al,
2004; Mani et al, 2008). Because a drug’s action on a target
gene product can yield an effect that is similar to a
hypomorphic or loss-of-function allele of the gene encoding
the drug target (Parsons et al, 2004; Hillenmeyer et al, 2008),
two drugs may be synergistic for the growth inhibition
phenotype if they target the products of two genes that have
a synergistic genetic interaction.
Several examples of genetically consistent synergy have
been reported, such as the synergy involving a combination of
either two mutations or two drugs that inhibit the DNA
polymerase and thymidine kinase of Herpes Simplex Virus
(Jacobsonetal,1995).Also,drugsynergybetweenTerbinaﬁne
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interaction between the target genes (Lehar et al, 2007).
Othermodelshavebeenproposedtoexplainthemechanism
of observed synergistic drug interactions (Jia et al, 2009). The
bioavailability model suggests that two drugs will be synergis-
tic if one drug’s action helps another drug’s availability in the
target cells (Zimmerman et al, 2007), either by increasing the
second drug’s entry to the cell or by decreasing the second
drug’s degradation. For example, it has been reported that 1,8-
Cineole enhances the effect of AZT, an anti-HIV drug, by
increasing skin permeability (Narishetty and Panchagnula,
2004). Consistently, a number of drugs known to disrupt cell
membranes, such as Triclosan in E. coli and ergosterol
pathway-targeting drugs in yeast, have been found to exhibit
many synergies (Ryder, 1992; Schweizer, 2001).
Combination therapies for which an underlying genetic
explanation exists are attractive from a therapeutic standpoint.
Such genetically determined drug synergies are expected to be
more speciﬁc to particular pathways, thus having a reduced
potential for unintended consequences. Concordantly, synergy
which arises via the bioavailability model comes with the
concern that bioavailability may be increased for many drugs
beyond the one for which synergy is desirable, including drugs
co-administered for other indications. However, it may not
always be possible to ﬁnd an efﬁcacious combination therapy for
which the genetic underpinnings are known. Indeed, it is unclear
whether correspondence between gene synergies and drug
synergies, which we refer to as ‘speciﬁc synergy’, is the
predominant form of drug synergy.
If some drugs are inherently more likely to participate in
synergistic combinations—for example, because they generally
increase the bioavailability of other drugs—then the search for
synergistic combinations might be accelerated by prioritizing
combinations that contain promiscuous synergizers. Because
‘promiscuous synergy’ bydeﬁnition encompasses manydifferent
drugs, it may be relativelycommonwhen compared with speciﬁc
synergy.
Results
We ﬁrst established an experimental framework for classifying the
interaction between two drugs as synergistic, independent, or
antagonistic. For each drug pair examined, we examined all
possiblecombinationsofsevenconcentrationsforeachdrug,such
that the concentration for each drug ranged from 0 to its minimal
inhibitory concentration (MIC). Synergistic or antagonistic inter-
action can then be classiﬁed according to signiﬁcant deviation
from non-interaction behavior under the Loewe additivity model
of drug synergy (Greco et al, 1995). The Loewe additivity model is
intuitively appealing, in that a drug does not interact with itself
under this model. As viewed on a two-dimensional grid, a drug
combined with itself will yield linear isophenotypic contours
(isobols), curves such that each point alongthe curve corresponds
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Figure 1 Experimental set-up for classiﬁcation of drug interactions. For each drug pair, growth rates were measured for all pairwise combinations of seven drug
concentrations, linearly increasing from 0 to the minimal inhibitory concentration (MIC). ‘Isophenotypic’ curves describing drug concentration combinations which yield
the same phenotype are shown on the left. Isophenotypic curves are expected to be parallel to the diagonal for independent drug pairs, concave for synergistic drug
pairs,andconvexforantagonisticdrugpairs,accordingtoLoeweadditivity.Foreachdrugpair,adruginteractionscore(a)quantifyingtheconcavityoftheisophenotypic
curve was computed, with a¼0 deﬁning independence and a taking negative or positive values when drugs are synergistic or antagonistic, respectively. Measurement
error in a was assessed by examining the distribution of a for 25 self–self drug combinations, and drug pairs that had signiﬁcantly smaller or larger a values were
classiﬁedassynergisticorantagonistic,respectively.Thewhiteregionshowsthemarginofvariabilitybetweenself–selfinteractions( 0.78oao0.68,95%conﬁdence
interval). Experimental examples of drug interactions are given on the right. In each example, Tacrolimus concentration is increased along the x axis. Drugs used
in increasing concentrations along the y axis are Tacrolimus for self–self, Myriocin for independence, Latrunculin B for synergy, and Bromopyruvate for antagonism.
For each example, sample isophenotypic curves are depicted in white. Yellow dots mark the longest isophenotypic curve, which was used to classify a drug interaction.
See Supplementary Figure 1 for plots of all 200 pairwise drug interaction tests conducted in the course of this study.
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growth phenotype. However, the contours will be convex when
two drugs are synergistic, and concave when they are antagonistic
(Figure 1). We used a mathematical model (see Materials and
methods) to quantify the shape of isophenotypic contours where
values near 0 indicate linearity (independence), negative values
indicate convexity (synergy), and positive values indicate
concavity (antagonism).
To measure experimental variation in this interaction score,
we evaluated 25 ‘self–self’ drug combinations that would be
expected to yield a score of 0 in the absence of measurement
errors. This allowed us to classify drug interactions as
independent, signiﬁcantly synergistic, or signiﬁcantly antag-
onistic, depending on where the interaction score falls relative
to the observed distribution of self–self interaction scores. We
also considered Bliss and Gaddum’s interaction models for such
binary classiﬁcations (Berenbaum, 1989; Greco et al, 1995);
however, we found that our model based on Loewe additivity
provided the most intuitive and robust classiﬁcation of drug
interactions (see Materials and methods). Importantly, growth
ratesforself–selfdruginteractionexperimentsexhibitedveryhigh
correlation along the symmetry axis (r¼0.98, Po2.2 10
–16),
indicating the reproducibility of our experimental system.
To assess the overlap between synergistic genetic interac-
tions and synergistic drug interactions, we focused on the
yeast S. cerevisiae, the organism for which the largest number
of synergistic genetic interactions is known. We compiled
a catalog of 113 known chemical/target relationships in
S. cerevisiae from the literature (Supplementary Table 1). All
chemical compounds that yield a growth ﬁtness defect when
administered as single agents (referred to in this study
as ‘drugs’) were considered, excepting compounds known
not to act as inhibitors of their target. We next integrated the
resulting drug-target catalog with known synergistic
genetic interactions (Baryshnikova et al 2010; Costanzo et al,
2010; Stark et al, 2011; see Materials and methods). This
yielded a set of 211 drug pairs predicted to be synergistic
according to the parallel pathway inhibition model (Supple-
mentary Table2).Toassessthesuccessofthesepredictions,38
of these drug pairs involving a total of 21 drugs were assessed
for synergy. Except for three different drugs (DYC, FEN, and
HAL) that were each used individually to inhibit Erg2, an
ergosterol pathway protein, we used only one drug to inhibit
eachspeciﬁcproteincorrespondingtoagenewithasynergistic
genetic interaction (see Table I for each drug’s targetname and
function). Nine ofthese thirty-eight testeddrug pairswerealso
predicted to be synergistic according to the bioavailability
model, as they included an ergosterol pathway-targeting drug.
We found that 14 of the 38 tested drug pairs predicted to be
synergistic using synergistic genetic interactions showed
signiﬁcant synergy (37% accuracy), while 11 of the 38 drug
pairs (29%) showed signiﬁcant antagonism (Figure 2).
Although a set of negative control predictions tested within
our framework would provide a better validation of the use of
Table I List of all drugs used in this study, their abbreviation, highest dose used, target (bold if essential) and target function. Drugs that were found to be promiscuous
are highlighted. Literature references are provided in Supplementary Table 1
Drug Abbreviation Dose (mg/ml) Target(s) Target function
5 ﬂuorouracil 5FU 28 Cdc21 Nucleotide metabolism
Aureobasidin A ABA 280 Aur1 Sphingolipid metabolism
Amphotericin B AMB 0.49 Erg28 Ergosterol metabolism
Anisomycin ANI 3.5 ?
Benomyl BEN 28 Tub1, Tub2, Tub3 Microtubule component
Bromopyruvate BRO 490 Pyk1 Glycolysis
CCCP C3P 21 ?
Calyculin A CAL 2.1 Glc7 Serine/threonine phosphatase
Cantharidin CAN 140 ?
Chlorzoxazone CHL 350 ?
Cisplatin CIS 80 DNA
Clozapine CLO 105 Cox17 Metallochaperone
Cycloheximide CYC 0.91 Rpl41A, Rpl41B Ribosomal protein
Dyclonine DYC 49 Erg2, Erg24 Ergosterol metabolism
Fenpropimorph FEN 1.54 Erg2, Erg24 Ergosterol metabolism
Haloperidol HAL 56 Erg2, Erg24 Ergosterol metabolism
Hygromycin HYG 7 Hoc1 Cell wall metabolism
Latrunculin B LAT 14 Act1 Actin
Lithium LIT 4500 Inm1, Met22 Inositol metabolism, nucleotide
metabolism
Methotrexate MET 1000 Dfr1 Nucleotide metabolism
Methyl methanesulfonate MMS 175 DNA
Myriocin MYR 0.350 Lcb1, Lcb2 Sphingolipid metabolism
Pentamidine PEN 70 Pnt1 Mitochondrial protein
Quinine QNN 1000 Tat2 Amino acid transport
Quinomycin QMY 30 ?
Radicicol RAD 56 Hsp82, Hsc82 Chaperone
Rapamycin RAP 0.0049 Tor1, Tor2 Protein kinase
Staurosporine STA 1.26 Pkc1 Serine/threonine kinase
Tacrolimus TAC 110 Cnb1 Phosphatase
Tamoxifen TAM 2.8 ?
Terbinaﬁne TER 10.5 Erg1 Ergosterol metabolism
Tunicamycin TUN 0.35 Alg7 Glycosylation
Wortmannin WOR 280 Stt4 Kinase
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we initially noted that the prediction accuracy of the parallel
pathway inhibition model was much higher than the
previously reported background rate of antifungal synergy of
4–10% (Borisy et al, 2003; Farha and Brown, 2010).
Of particular note, all of the nine drug pairs that included an
ergosterolpathway-targetingdrug also exhibitedsynergy (100%
accuracy). Indeed, these nine drug pairs—which represented
only 24% of tested pairs—yielded 64% of the synergies among
tested pairs, supporting the idea that drugs increasing bioavail-
ability can provide an enhanced rate of synergy (P¼1.2 10
–5,
Fisher’s exact test). That ergosterol pathway-targeting drugs
were enriched for synergy indicated that different drugs may
have inherently different background synergy rates. In an effort
to assess background synergy rates of different drugs, we tested
all drug pairs in a square matrix of 13 drugs (Figure 3). Of these
13 drugs, 10 were partners in successfully predicted synergistic
drug pairs in the initial screen (TER, FEN, HAL, DYC, PEN, TAC,
LAT, BEN, STA, and RAP; see Table I for abbreviation key). Two
drugs were partners in unsuccessful predictions (TUN and CAL)
and BRO was added to the list arbitrarily.
Ofthe63drugpairsinourtestspacethatwerenotpredictedto
target synergistic gene products, we were surprised to observe
that 21 (33%) showed synergy. The number of synergies each
drugexhibitedwasnotuniform(w
2test,P¼0.024),indicatingthe
non-uniformity of background synergy rates for these 13 drugs.
This observation suggests that there is no single universal
background rate of synergy, which can be used as a basis for
comparison of the success for a synergy prediction method.
As an initial attempt to account for background rates of
synergy, we considered the baseline synergy rate of each drug
tested in our 13 13 matrix in turn. For each drug, we
examined whether drug pairs involving that drug were more
likely to exhibit synergy if they corresponded to a genetic
interaction. After correcting for multiple hypothesis testing,
we found no evidence for signiﬁcant enrichment of synergy
among drug pairs corresponding to synergistic genetic inter-
actions (using a threshold of 0.05 for adjusted P-values). This
was despite the fact that the choice of drugs to fully test within
the 13 13 matrix was initially biased to include drug pairs
corresponding to genetic interaction. Thus, a consideration of
baseline rates of synergy for each drug eliminates the
signiﬁcance of our observed correlation between synergistic
genetic interaction and drug synergy.
Where drug synergy does correspond to genetic interaction,
we wished to further analyze whether the observed drug
synergies are the result of synergistic genetic interactions
between the drug targets. Therefore, we conducted drug
interaction experiments with an S. cerevisiae strain for
which the CNB1 gene—encoding the target of TAC (Parsons
et al, 2004)—was deleted. CNB1 has a synergistic genetic
interaction with ACT1 and PKC1 (targets of STA and LAT,
respectively), and we have shown that drug pairs TAC–LAT
and TAC–STA are highly synergistic. We hypothesized that if
the synergies between these drugs arise from the same
mechanism as the synergistic genetic interactions, then these
drug synergies should not exist in a cnb1 null mutant.
However, we observed both of these drug synergies in cnb1D
strains. This suggests that the observed synergies of drug pairs
TAC–LATand TAC–STA, successfully predicted on the basis of
genetic interaction, are not mediated solely by the CNB1-ACT1
and CNB1-PKC1 synergistic genetic interactions. The observa-
tion that TAC exhibits synergies even when its known target
has been deleted also suggests that there are other targets of
TAC in S. cerevisiae. These results exemplify the idea that the
existence of multiple targetsfor each drug can complicate tests
of the correspondence between genetic interaction and drug
synergy.
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Figure 2 Synergy tests between 38 drug pairs that target proteins encoded by synergistic genes. (A) Drug pairs were combined in 8 8 matrices where the
concentration of one drug was linearly increased along each axis. The lowest concentration was 0 and the highest concentration was chosen close to the MIC for each
drug.Fourteendrugpairsshowedsigniﬁcantsynergy(markedwithS)whileelevenweresigniﬁcantlyantagonistic(markedwithA).Thirteendrugpairsyieldedscoresthat
fell withinthe distribution observed for self–self drug pairs, andwere classiﬁed asindependent (unmarked). (B)Network representation of the druginteractions shownin
(A). Edges reﬂect the interaction type between two drugs and the node pie charts represent the ratio of different types of interactions each drug has in this data set
(green: synergy, white: independent; red: antagonism). For drug name abbreviations, see Table I. One example for drug synergy prediction using synergistic genetic
interactions: MYR targets Lcb2andQNN targets Tat2is alsoshown.There is aknownsynergistic geneticinteraction between LCB2 andTAT2,whichpredicts thatMYR
and QNN will be synergistic according to the parallel pathway inhibition model of drug synergy. However, these drugs were found to be antagonistic.
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synergy rates suggested a strategy whereby pairs that involve
at least one of these promiscuous synergizers are prioritized for
testing. The number of synergies shown by each drug is a
proxy for their background synergy rate. However, each of
these synergies may be due to the high background synergy
rates of the partner drugs. For a more robust analysis of
background synergy rates of drugs, we clustered the interac-
tion score proﬁles of the drugs in the 13 13 matrix. Not
surprisingly, the three Erg2-targeting drugs were clustered
together. Interestingly, these three and the other ergosterol
pathway-targeting drug TER were clustered with TAC and
PEN, despite the fact that the latter twodrugs arenot known to
disrupt the cell membrane. All pairwise interactions within
this set of six drugs were synergistic, except between Erg2-
targeting drugs (which may be explained by competition
between these drugs at the same target site). We refer to
members of this cluster as promiscuous synergizers.
We also carried out a network analysis using the drug
interaction network shown in Figure 3B in order to determine
the smallest set of drugs that could ‘explain’ all observed drug
synergies. When two drugs acted synergistically, we attributed
thedrugsynergytothe drugwiththe highest level of background
synergy. By individually removing the drugs with the highest
background synergy rate and recomputing the number of
synergies each drug exhibits in the resulting network, we found
that the parsimonious classiﬁcation of six drugs as promiscuous
explained all the drug synergies in this data set. This smallest set
coincided exactly with the promiscuous synergizers found by
clustering analysis. Because the remaining seven drugs in our
analysis exhibited relatively few synergies, we refer to these as
chaste synergizers.
We next wondered whether promiscuity and chastity of
drugs are intrinsic drug properties that would predict drug
interaction behavior outside of the 13 13 drug matrix in
which these properties were learned. Therefore, we further
examined three promiscuous (TER, PEN, and TAC) and three
chaste drugs (LAT, STA, and BEN), assessing synergy for each
of these six against an array of 14 arbitrarily chosen drugs
(Figure 4). Fourteen of sixteen synergies observed in this
screen included a promiscuous synergizer drug, indicating a
signiﬁcant enrichment (Fisher’s exact test, P¼8.7 10
–4) and
supportingtheideathatpromiscuityis an intrinsicpropertywith
predictivevalue.Remarkably,LATandSTAdidnotshowsynergy
with any of the 14 drugs, supporting the idea that they are
intrinsically chaste. We found that BEN showed synergy with
two arbitrarily chosen drugs (C3P and QMY) and it clustered
with the other three promiscuous drugs in this new data set.
While further experiments will be required to conﬁdently
characterize BEN as either promiscuous or chaste, these
observations support the inherence of promiscuity for TER,
PEN, and TAC. These results further bolster the conclusion that
background synergy rates of different drugs are highly non-
uniform.
We next wondered whether drugs have intrinsic tendencies
towards antagonism, as well as synergy. An analysis of the
data in the 13 13 square matrix of drug interactions does not
reject the null hypothesis that background antagonism rates of
drugs are uniform (w
2 test, P¼0.097). However, we note that
BRO, which showed antagonism with every drug against which
it was tested, was signiﬁcantly enriched for antagonisms
(P¼2.9 10
–6). Moreover, the synergy and antagonism rates of
individual drugs have a signiﬁcant negative correlation
(r¼ 0.78, P¼1.6 10
–3). Thus, the antagonism background
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accelerating the search for synergistic drug combinations.
Discussion
In this study, we systematically explored drug combinations to
evaluate speciﬁcand promiscuous models ofdrug synergy. We
developed a sensitive drug interaction classiﬁcation assay and
used it to ﬁnd 38 synergistic drug pairs, of which only 1
(Terbinaﬁne–Rapamycin) had been previously reported
(Lehar et al, 2007).
To identify cases of speciﬁc synergy, predictedbysynergistic
genetic interaction, we integrated a newly assembled catalog
of drug targets with the synergistic genetic interaction
network. Although we tested 38 drug pairs corresponding to
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antagonism; independence edges are omitted for clarity). Gray circle indicates the promiscuous synergizers learned from the drug interaction network in Figure 3B. For
drug name abbreviations, see Table I.
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difﬁcult to assess whether these drug synergies are better
explained by genetic interaction or promiscuous synergy.
Indeed, after accounting for background rates of synergy for
each drug, our results did not show a signiﬁcant enrichment
for drug synergy among drugs targeting the products of
genetically interacting genes.
There are many potential explanations for this observation.
First, either or both of the drugs may not inhibit their targets
completely or at all. Although chemogenomic studies have
shown that the deletion of a target gene is often similar to
treatmentbythedrug(Hillenmeyeretal,2008),andalthoughwe
excluded drugs that were known not to act as inhibitors, not all
of the drugs within our tested set are known to act as inhibitors.
Second, each drug may have multiple targets. Action on
additional targets may raise the background rate of drug
synergy, making it more difﬁcult to observe a signiﬁcant
enrichment for synergy predicted via genetic interaction. In
rare cases, action on these additional targets may even
suppress the effects of action on the known targets used to
make drug synergy predictions.
Third, some drug targets in our literature-derived catalog
mayhavebeenerroneouslyidentiﬁed.Themisidentiﬁcationof
targets would naturally have a profound effect on the apparent
overlap between genetic interaction and drug synergy.
Fourth, intrinsic promiscuity of individual drugs may be the
dominant factor in predicting drug synergy, again making it
difﬁcult to discern signiﬁcant enrichment for synergy for drug
pairs that correspond to genetic interactions. Indeed, our
results support the idea that mechanisms other than parallel
pathway inhibition of drug synergy are largely responsible for
thesynergisticdruginteractionsthatareobservedinourstudy.
Another model of drug synergy proposes that drugs may
exhibit synergy if a drug’s action helps a second drug’s
availability in the cell (bioavailability model). This model was
systematicallyevaluated in our study, by testing synergy of drug
pairs that included drugs that are known to destabilize the cell
membranebytargetingtheergosterolpathwayinyeast.Wehave
shown that such drug pairs are enriched for drug synergy. We
further classiﬁed drugs that partake in numerous synergies as
‘promiscuous synergizers’ (Farha and Brown, 2010). Interest-
ingly, two of the drugs we classiﬁed as promiscuous synergizers
are not known to destabilize the membrane. Furtherstudies will
be required to determine whether there are other classes of
promiscuous synergizers that do not correspond to the bioavail-
ability model of drug synergy. In fact, after 450 years since the
bioavailability model for drug synergy was suggested (Jawetz
and Gunnison, 1953), direct experimental evidence for this
mechanism has not been produced. However, the analyses
presented here strongly suggest that promiscuous synergizers
enhance the potency of other drugs. Therefore, promiscuous
drugs have a potentially valuable use in accelerating the search
for synergistic drug combinations.
Additional models explaining drug synergy have been
proposed. The physical interaction model proposes that two
drugs physically interact to make amore potent compound.This
model, which is largely discredited (Jawetz and Gunnison,
1953), was not evaluated here. The same target model proposes
that two drugs will be synergistic if they target different sites on
the same protein (Krogstad and Moellering, 1986). Incidentally,
it has also been proposed that two drugs will be antagonistic if
theytargetsimilarsitesonaprotein(competitivebindingmodel;
Krogstad and Moellering, 1986). In this study, we tested all
pairwise combinations of three drugs that target the same
protein, Erg2. Two of these drug pairs were found to be
antagonistic, while none of them exhibited synergy. These
observations support the idea that these three Erg2 binding
drugs, as predicted by the similarity of their chemical structures,
bindtosimilarpocketsonthetargetprotein(Giaeveretal,2004).
Our results show clearly that background synergy rate is
drug dependent. This observation is critical for the assessment
ofanydrugsynergypredictionmethod,sinceitshouldaccount
for the background synergy rates of all drugs that are in a drug
combination.
The wealth of drug interaction results that are obtained in
our study allows us to comment on mechanisms of drug
antagonism. Two models for drug antagonism have been
proposed. The ﬁrst, referred to as the competitive binding
model, was mentioned above with the same target model for
drug synergy (Krogstad and Moellering, 1986). The other drug
antagonism model suggests that drug antagonism occurs
when a drug’s action impedes the metabolism of the cell so
that the second drug cannot exhibit its optimal effect
(metabolic imbalance model; Bollenbach et al, 2009; Xavier
andSander,2010).Concordantly,wenotethatBromopyruvate,
which is known to inhibit glycolysis, was antagonistic with all
drugs tested, including promiscuous synergizers. Thus, our
results hint that background drug antagonism rates are also
non-uniform. Notably, a previous study suggested, in agree-
ment with the metabolic imbalance model for drug antagon-
ism, that drugs that target unrelated pathways are more likely
to show antagonism (Lehar et al, 2007).
The study presented here provides a systematic exploration
of drug synergies in the context of mechanistic models of drug
synergy. We found 14 drug pairs to be consistent with speciﬁc
synergy, that is, for which genetic interaction provides some
evidence that the drugs target parallel pathways. Our results
also suggest that discovery of synergistic drug pairs can be
accelerated by considering the background synergy rate
individual drugs. Although the predominant form of drug
synergy in our study is promiscuous synergy, it remains
possible that genetic interaction will be a good predictor of
drug synergy in other contexts. For example, genetic interac-
tion might predict synergies between chaste synergizers.
Proper study of this question awaits an expansion in the
number of known drug/target relationships and a further-
expanded map of genetic interactions.
Materials and methods
Experimental materials and methods
5FU, ANI, BEN, BRO, C3P, CHL, CIS, DYC, FEN, HAL, LIT, MET, MMS,
PEN, QNN, TAM, and TER were purchased from Sigma-Aldrich. AMB,
CAL, CAN, CLO, CYC, HYG, LAT, MYR, QMY, RAD, RAP, STA, TAC,
TUN, and WOR were purchased from AG Scientiﬁc. See Table I for
abbreviation key. ABA was purchased from Clontech. All drugs were
dissolvedinDMSO(exceptCisplatinwhichwasdissolvedinDMF)and
kept at  201C (except Cisplatin and Bromopyruvatewhichwasfreshly
prepared due to loss of activity upon freezing). All experiments were
conducted with S. cerevisiae strain BY4741, purchased from Open
Biosystems. Yeast cells were grown in YPD (1% yeast extract, 2%
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OD600 of 0.01 in YPD with the desired drug concentrations controlled
for solvent concentrations. Cells were grown for 24h in 96-well plates
in a Tecan F200 microplate reader, with OD595 readings of cell density
recorded every 15min. For each drug–drug interaction assay, we took
6144cell-densitymeasurements(detailedgrowthtimecoursesforeach
of 64 concentration combinations with 96 time points in each time
course). Synergy assays were performed for 200 drug pairs in total, so
that a total of 41 million measurements were performed during this
study. We used the area under growth curve of each condition as a
metric of cell growth, after discarding the ﬁrst 10 measurement points.
The entire collection of growth measurement data is available as
Supplementary Data Set 1.
Synergy assessment
To assess synergy, we used the Loewe Additivity Model, which deﬁnes
a drug’s interactionwith itselfas no interaction(fora comparisonwith
other drug synergy models, see below) (Greco et al, 1995). Eight
different concentrations of two drugs were combined in a two-
dimensional grid, where the lowest concentration for each drug was 0
and the highest concentration for each drug was close to the MIC. The
concentration of one drug was linearly increased on each axis (see
Table I for the highest dose used for each drug).
The marginal effect of each drug alonewas determined byassessing
the growth under 0 concentration of the other drug. Additional grid
points were imputed (using Akima interpolation; Akima, 1970) and
contours were plotted, connecting the marginal growth rates of each
drug through the grid along ‘isophenotypic’ curves. The maximum of
the lowest marginal growths of each drug was used as a threshold,
where any growth lower than this value was not considered (as
contours could no longer connect the two marginal axes). The grids
were then rescaled from 0 (low growth) to 1 (highest growth) and the
longest isophenotypic curve (i.e., the curve described by the greatest
number of data points) was selected for assessment. The following
model was used to summarize this curve:
a ¼ log
x
1   x
  
  log
y
1   y
  
where x and y are the normalized drug concentrations and a is a free
parameter describing the ‘bend’ of the curve. When a¼0, the contour
connectingthe two marginal growth rates is linear (e.g., describingthe
case when a drug is tested against itself). When ao0o ra40, drug
synergy or antagonism is concluded, respectively.
To assess measurement error, 25 drugs were experimentally tested
for interaction with itself (since by deﬁnition, there is no synergy for a
drug with itself, any deviations of a from 0 represent measurement
errors). We modeled the a values of drug self-interaction experiments
as normal (as we did not ﬁnd sufﬁcient evidence to believe otherwise,
KS test, D¼0.15, P¼0.58), with a mean of ^ m of –0.05 and standard
deviation ^ s of 0.37. Hence, two drugs were considered synergistic or
antagonistic when their a value was signiﬁcantly smaller (ao 0.78)
or larger (a40.68) than the experimental mean of the drug self
interaction scores, respectively.
The synergy levels between drugs were also assessed using Bliss
Independence and Gaddum’s non-interaction models. For Bliss
Independence, parameter b that minimizes the following metric was
computed to assess the overall synergy between drugs 1 and 2:
X
½fðdrug1½x  þ drug2½y Þ b fðdrug1½x Þ fðdrug2½y Þ 
2
and for Gaddum’s non-interaction model, parameter g that minimizes
the following metric was computed:
X
½fðdrug1½x  þ drug2½y Þ g maxffðdrug1½x Þ; fðdrug2½y Þg 
2
where f(drug1[x]) represents the cell growthin drug 1 at concentration
x, and b and g are free parameters describing the deviation from null
model surfaces. According to these drug interaction models, b¼1o r
g¼1 represents non-interaction between two drugs. When these
parameters are smaller or larger than 1, synergy or antagonism is
concluded, respectively. Parameters b and g for self–self drug
interactions were approximately normally distributed. A comparison
of the estimated b values with a scores estimated above showed that
these two parameters had a very high correlation (r¼0.79, Po10
–43);
however, g values showedcorrelationwithneither a nor b parameters.
Moreover, according to the estimated g values for our experiments,
none of the tested drug pairs showed synergy or antagonism. While a
parameters found only 1 self–self interaction as interacting (Po0.05),
the Bliss Model found 2 self–self interactions as interacting (P40.05).
In the light of these observations, we concluded that Bliss Indepen-
dence and Gaddum’s non-interaction models, while useful for ﬁnding
synergies between speciﬁc concentrations of two drugs, does not give
robust results for an absolute measure of synergy between two drugs.
Hence, we used the Loewe additivity model as our drug synergy-
antagonism classiﬁer.
Genetic interaction data
Inadditiontopublishedsourcesofgeneticinteractiondata(Baryshnikova
et al, 2010; Costanzo et al,2 0 1 0 ;a n dS t a r ket al,2 0 1 1 )w ea l s ou s e d1 1
unpublished interactions from the Boone and Andrews Labs: AUR1-
MET22, ERG2-ACT1, HOC1-TOR2, ACT1-TOR1, ACT1-CNB1, INM1-TOR2,
INM1-CNB1, LCB2-TAT2, LCB2-HSP82, LCB2-CNB1 HSC82-PKC1.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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